Proportion of patients with resolution or improved symptoms at days 3 to 7 · patients with acute sinusitis
Oral corticosteroids probably leads to higher proportion of patients with resolution or improved symptoms at days… compared with placebo or NSAID (moderate certainty).
3 findings from 1 review
RR 1.33 [1.09, 1.62]
5 studies · 1043 participants
Moderate
RR 1.4 [1.08, 1.81]
4 studies · 869 participants
Low
RR 1.12 [0.87, 1.44]
1 study · 174 participants
Moderate
Proportion of patients with resolution or improved symptoms at days 4 to 14 · patients with acute sinusitis
Oral corticosteroids probably leads to higher proportion of patients with resolution or improved symptoms at days… compared with placebo or NSAID (moderate certainty).
2 findings from 1 review
Proportion of patients with resolution or improved symptoms at days 4 to 14 ‐ Co‐treatment with antibiotics · patients with acute sinusitis
Oral corticosteroids may leads to higher proportion of patients with resolution or improved symptoms at days… compared with placebo or NSAID (low certainty).
1 finding from 1 review
Adverse events · patients with acute sinusitis
1 finding from 1 review
Intervention not reported
Temperature ‐ cohort studies orally · children 9 months to 15 years old
It is very uncertain whether the intervention changes temperature ‐ cohort studies orally (very low certainty).
1 finding from 1 review
Duration of time requiring non‐oral fluid therapy (time to resume full oral feeding) · health problem or population
1 finding from 1 review
Primary outcome: subjective symptom score (mean) ‐ 3 hours after dosing · adult patients with the common cold
1 finding from 1 review
Primary outcome: subjective symptom score (AUC) ‐ 3 hours after dosingOral · adult patients with the common cold
1 finding from 1 review
Primary outcome: subjective symptom score (mean) ‐ 3 hours after dosing · adult patients with the common cold
1 finding from 1 review
Secondary outcome: all adverse eventsOral · adult patients with the common cold
Summary of findings for multi‐dose nasal decongestant showed no clear difference in secondary outcome: all adverse eventsOral compared with placebo (low certainty).
1 finding from 1 review
Incidence of acute URTIs during the study period (the number of acute URTIs over a period of time) · children up to the age of 7 at risk of upper respiratory tract infection
Summary of findings table ‐ Vitamin A supplements showed no clear difference in incidence of acute URTIs during the study period (the number of… compared with placebo (low certainty).
1 finding from 1 review
Incidence of acute URTIs during the study period (proportion of participants with an acute URTI) · children up to the age of 7 at risk of upper respiratory tract infection
1 finding from 1 review
Adverse events · children up to the age of 7 at risk of upper respiratory tract infection
1 finding from 1 review
Severity of subjective symptoms (mean duration of acute URTI) · children up to the age of 7 at risk of upper respiratory tract infection
1 finding from 1 review
Time to occurrence of acute URTI ‐ not reported · children up to the age of 7 at risk of upper respiratory tract infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of cases with complications ‐ not reported · children up to the age of 7 at risk of upper respiratory tract infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Rate of hospitalisation ‐ not reported · children up to the age of 7 at risk of upper respiratory tract infection
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Global evaluation · otherwise healthy adults and children with common cold symptoms
Antihistamine‐decongestant probably leads to lower global evaluation compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects: all · otherwise healthy adults and children with common cold symptoms
Analgesic‐decongestant leads to higher adverse effects: all compared with placebo (high certainty).
1 finding from 1 review
Adverse effects: drowsiness, hypersomnia, lethargy, excessive sleepiness, and other central nervous system adverse effects · otherwise healthy adults and children with common cold symptoms
Analgesic‐decongestant showed no clear difference in adverse effects: drowsiness, hypersomnia, lethargy, excessive… compared with placebo (moderate certainty).
1 finding from 1 review